🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy

Recruitingn/aAges 40 Years - 69 YearsMaleEndeavor Health
NCT05295407 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Condition: Prostate cancer Intervention: Biopsy and inherited risk assessment

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Consecutive patients undergoing prostate biopsy for detection of prostate cancer * Aged 40 to 69 years * Four ethnicity groups (Caucasian, African Americans, East Asians, Latinos) * PSA between 2.5-10 ng/mL Exclusion Criteria: * Previous diagnosis of prostate cancer. * Ethnicity outside the inclusion criterion (including mixed ethnicity). * Any prior PSA test result outside the range of inclusion criterion.
💊

What it tests

  • Genetic Assessment
📍

Where

1 site
NorthShore University HealthSystem
Evanston, United States
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy